The sensitivity of tumorigenesis and tumor progression to the relatively small differences between haplo-insufficient and wild-type Myc levels, or between diploid and tetraploid cells to sponsor hemangiosarcomagenesis, argues that partial inhibition of Myc function may suffice to block or significantly retard disease progression in most cancers. Here, MYC is linked to cancer.